Iovance Biotherapeutics Financial Overview
Iovance Biotherapeutics's market cap is currently $873.33M. The company's EPS TTM is $-0.25; its P/E ratio is -1.83; Iovance Biotherapeutics is scheduled to report earnings on November 6, 2025, and the estimated EPS forecast is $-0.17. See an overview of income statement, balance sheet, and cash flow financials.
